Clinical Trial

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Study acronym: PLATINUM US
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence. The study will be conducted in two periods: Main Period (MP) and Open label Extension Period (OLEX).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-23
Trial Details
NCT Number NCT07122193
Lead Sponsor Merz North America, Inc.
Conditions Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors, Membrane Transport Modulators, Molecular Mechanisms of Pharmacological Action, Cholinergic Agents, Neurotransmitter Agents +2 more
Enrollment 300 participants
Start Date 2025-08-27
Primary Completion 2026-10 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-22